amodiaquine
Trials 81 · started per year
Also used as a comparator or background therapy in 37 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00563914 Comparator | Oct 2007 → Nov 2008 | malaria | Sanofi | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT01955382 Background | Sep 2013 → Jul 2015 | Plasmodium falciparum malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT01407887 Comparator | Aug 2011 | Plasmodium falciparum malaria | Heidelberg University | Completed | No outcome recorded |
| Phase 2 | NCT00545935 Comparator | Jul → Oct 2007 | malaria | Heidelberg University | Completed | No outcome recorded |
| Phase 2 | NCT00323622 Background | Apr 2005 → May 2007 | malaria | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT02453308 Comparator | Aug 2015 → Mar 2018 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| Phase 2/3 | NCT00941785 Comparator | Jul → Dec 2009 | malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 313 trials | ||||||
| Phase 3 | NCT06173206 Comparator | Jun → Dec 2024 | malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 3 | NCT03939104 Comparator | Jun 2021 → Jan 2023 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| Phase 3 | NCT04319380 Comparator | Apr 2020 → Mar 2022 | Plasmodium falciparum malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 3 | NCT04149106 Comparator | Jul 2019 → Dec 2022 | Plasmodium falciparum malaria | University Clinical Research Center, Mali | Unknown | No outcome recorded |
| Phase 3 | NCT03143218 Comparator | Apr 2017 → Mar 2020 | Plasmodium falciparum malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 3 | NCT02211729 Background | May 2014 → Dec 2017 | malaria, respiratory tract infectious disorder | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 3 | NCT01231113 Comparator | Jul 2011 → Dec 2012 | Plasmodium falciparum malaria | Kwame Nkrumah University of Science and Technology | Completed | No outcome recorded |
| Phase 3 | NCT01288820 Comparator | Jan 2011 → Apr 2012 | Plasmodium vivax malaria | University of Oxford | Completed | No outcome recorded |
| Phase 3 | NCT01152931 Comparator | Aug → Nov 2010 | malaria | University of Lagos, Nigeria | Completed | No outcome recorded |
| Phase 3 | NCT00944840 Comparator | Sep 2008 → Jul 2009 | malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 3 | NCT00852371 Comparator | Feb → Jun 2008 | malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 3 | NCT00529620 Comparator | Sep → Dec 2007 | malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 3 | NCT00297882 Comparator | Jul 2006 → Apr 2009 | malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 412 trials | ||||||
| Phase 4 | NCT06300970 Comparator | Aug 2022 → Aug 2023 | Plasmodium falciparum malaria | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 4 | NCT05323721 Comparator | Jun → Nov 2022 | malaria | Malaria Consortium | Unknown | No outcome recorded |
| Phase 4 | NCT05343312 Comparator | Mar 2022 → Sep 2023 | Plasmodium falciparum malaria | Manhiça Health Research Centre | Completed | No outcome recorded |
| Phase 4 | NCT05186363 Comparator | Jan → Jun 2022 | malaria | Malaria Consortium | Unknown | No outcome recorded |
| Phase 4 | NCT04370977 Comparator | Mar → Sep 2018 | malaria | Manhiça Health Research Centre | Completed | No outcome recorded |
| Phase 4 | NCT03178643 Comparator | Jan 2018 → Dec 2020 | Plasmodium falciparum malaria | Duke University | Completed | No outcome recorded |
| Phase 4 | NCT02741024 Comparator | Oct 2013 → Dec 2014 | malaria | Medecins Sans Frontieres, Netherlands | Completed | No outcome recorded |
| Phase 4 | NCT02168569 Comparator | Jun 2011 → Jan 2012 | Plasmodium falciparum malaria | Manhiça Health Research Centre | Completed | No outcome recorded |
| Phase 4 | NCT04877626 Comparator | Sep 2008 → Oct 2009 | Plasmodium falciparum malaria | National University of Colombia | Completed | No outcome recorded |
| Phase 4 | NCT00374205 Comparator | Sep 2006 → Oct 2007 | Plasmodium falciparum malaria | Bernhard Nocht Institute for Tropical Medicine | Terminated | No outcome recorded |
| Phase 4 | NCT03768908 Comparator | Jan → Jul 2005 | Plasmodium falciparum malaria | Professor Anders Björkman | Completed | No outcome recorded |
| Phase 4 | NCT03764527 Comparator | Nov 2002 → Feb 2003 | Plasmodium falciparum malaria | Professor Anders Björkman | Completed | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT05354258 Background | Jun → Nov 2022 | Nematoda infectious disease, malaria, schistosomiasis | London School of Hygiene and Tropical Medicine | Unknown | No outcome recorded |
| — | NCT04238845 Background | Jul 2020 → Jul 2021 | malaria, protein-energy malnutrition | Institut de Recherche en Sciences de la Sante, Burkina Faso | Unknown | No outcome recorded |
| — | NCT01967472 Comparator | Sep → Dec 2013 | malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| — | NCT00460369 Comparator | Apr → Nov 2007 | malaria | Research Institute for Development | Completed | No outcome recorded |
| — | NCT00285662 Comparator | Jun 2006 → May 2010 | anemia, malaria | Papua New Guinea Institute of Medical Research | Completed | No outcome recorded |
Evidence & citations 19 cited values
Every value below carries the sentence it was read from. 119 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | amodiaquine | “Patients received Cospherunate (50 mg Artésunate/125 mg Amodiaquine) at the rate of 2 tablets orally twice daily for 6 days and Azythromycine 250 mg orally at the rate of 2...” NCT04502342 ↗116“Artesunate-amodiaquine fixed dose combination (FDC) (Artesunate Amodiaquine Winthrop® Sanofi Aventis); Artesunate 25mg/amodiaquine 67.5mg; Artesunate 50mg/amodiaquine 135mg ;...” NCT00902811 ↗ “Following the recommendation of the WHO, Ghana changed its malaria treatment guidelines adopting artesunate and amodiaquine as first line for the treatment of uncomplicated...” NCT04301531 ↗ “Amodiaquine (10 mg/kg over 3 days) and Sulfadoxine Pyrimethamine (25 mg of sulfadoxine + 1.25 mg of pyrimethamine per kg in a single dose) or placebo administered over 3 rounds...” NCT00738946 ↗ “This preventive measures involves administering antimalarial drugs (Amodiaquine-Sulfadoxine-Pyrimethamine) to children aged 6- 59 months on a monthly basis during the high...” NCT04238845 ↗ “We will assess the efficacy of a three day course of amodiaquine plus three days of artesunate (AQ3/AS3) for the treatment of symptomatic, uncomplicated P. falciparum infections.” NCT00425763 ↗ “Artesunate 25mg / amodiaquine 67.5mg: 1 tab/day for 3 days in children 5 to 8.9 kg Artesunate 50mg / amodiaquine 135mg: 1 tab/day for 3 days in children 9 to 17.9 kg” NCT01567423 ↗ “One cycle of SMC consisting of sulphadoxine - pyrimethamine (SP) 500mg/25 mg, and amodiaquine (AQ) 150mg on day 1, and AQ 150mg on days 2 and 3.” NCT04319380 ↗ “Children will receive 500mg sulfadoxine plus 25mg pyrimethamine as one tablet, and 153mg amodiaquine (as hydrochloride) as one tablet on Day 0” NCT06173206 ↗ “Monthly administration of sulfadoxine-pyrimethamine plus amodiaquine, combined with community case management” NCT01449045 ↗ “AQ Amodiaquine is a Mannich base 4 amino-quinoline that interferes with parasite haem detoxification.” NCT05979896 ↗ “a three-day course of either chloroquine (Ethiopia) or artesunate-amodiaquine (Madagascar)” NCT06923592 ↗ “For children aged 6-11 months: sulfadoxine 250mg/pyrimethamine 12.5mg and amodiaquine 75mg” NCT03035305 ↗ “The standard SMC regimen includes sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ).” PMID 38252481 ↗ Jan 2024 “Atovaquone (ATV),Proguanil (PG) 1000-400 mg + Amodiaquine (AQ) 612 mg on days 1,2, 3.” NCT04002687 ↗ “plus Amodiaquine (150mg) twice daily for 3 days according to weight” NCT03355664 ↗ “and amodiaquine (AQ) 150mg on day 1, and AQ 150mg on days 2 and 3” NCT03143218 ↗ “Amodiaquine (200mg) according to age, given daily for 3 days” NCT01454752 ↗ “Efficacy and safety of fixed-dose artesunate-amodiaquine vs.” PMID 25436614 ↗ Dec 2014 “sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ)” NCT05186363 ↗ “Three daily doses of amodiaquine phosphate 10mg/kg” NCT00941785 ↗ “one 25mg artesunate and 67.5mg amodiaquine tablet” NCT05343312 ↗ “Amodiaquine (200mg base) 25mg/kg over 3 days” NCT00561899 ↗ “Amodiaquine for 3 days” NCT02453308 ↗ |
| Known as | Amodiaquin | ChEMBL registry synonym — accepted as the source's own label CHEMBL682 ↗ |
| Known as | Amodiaquina | ChEMBL registry synonym — accepted as the source's own label CHEMBL682 ↗ |
| Known as | Amodiaquine dihydrochloride dihydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL682 ↗ |
| Known as | Amodiaquine hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL682 ↗ |
| Known as | AMODIAQUINE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL682 ↗ |
| Known as | Amodiaquine hydrochloride dihydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL682 ↗ |
| Known as | Amodiaquini hydrochloridum | ChEMBL registry synonym — accepted as the source's own label CHEMBL682 ↗ |
| Known as | Amodiaquinum | ChEMBL registry synonym — accepted as the source's own label CHEMBL682 ↗ |
| Known as | amodiquina | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04877626 ↗ |
| Known as | Camoquin hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL682 ↗ |
| Known as | GNF-Pf-5648 | ChEMBL registry synonym — accepted as the source's own label CHEMBL682 ↗ |
| Known as | NSC-13453 | ChEMBL registry synonym — accepted as the source's own label CHEMBL682 ↗ |
| Known as | NSC-755863 | ChEMBL registry synonym — accepted as the source's own label CHEMBL682 ↗ |
| Known as | SJ000110703 | ChEMBL registry synonym — accepted as the source's own label CHEMBL682 ↗ |
| Known as | Sunoquine | ChEMBL registry synonym — accepted as the source's own label CHEMBL682 ↗ |
| Known as | TCMDC-123932 | ChEMBL registry synonym — accepted as the source's own label CHEMBL682 ↗ |
| Modality | Other / unclassified | “Artemisinin-based combination treatment” NCT04618523 ↗ |
| Route | Oral | “25 mg/kg oral AQ over a period of three days” NCT00261222 ↗ |